Multiple myeloma (MM), the disorder of plasma cells, is the second most common type of hematological cancer and is responsible for approximately 20% of deaths from hematological malignancies. The current gold standard for MM diagnosis includes invasive bone marrow aspiration. However, it lacks the sensitivity to detect minimal residual disease, and the nonuniform distribution of clonal plasma cells (CPCs) within bone marrow also often results in inaccurate reporting. Serum and urine assessment of monoclonal proteins, such as Kappa light chains, is another commonly used approach for MM diagnosis. Although it is noninvasive, the level of paraprotein elevation is still too low for detecting minimal residual disease and nonsecretive MM. Circulating CPCs (cCPCs) have been reported to be present in the peripheral blood of MM patients, and high levels of cCPCs were shown to correlate with poor survival. This suggests a potential noninvasive approach for MM disease progress monitoring and prognosis. In this study, we developed a mechanical property-based microfluidic platform to capture cCPCs. Using human myeloma cancer cell lines spiked in healthy donor blood, the microfluidic platform demonstrates high enrichment ratio (>500) and sufficient capture efficiency (40%–55%). Patient samples were also assessed to investigate the diagnostic potential of cCPCs for MM by correlating with the levels of Kappa light chains in patients.
REFERENCES
1.
R.
Siegel
, K. D.
Miller
, and J.
Ahmedin
, “Cancer statistics
,” CA Cancer J. Clin.
67
(1
), 7
–30
(2017
). 2.
G. S.
Nowakowski
et al, “Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma
,” Blood
106
(7
), 2276
–2279
(2005
). 3.
R.
Bezděková
, M.
Penka
, R.
Hájek
, and L.
Říhová
, “Circulating plasma cells in monoclonal gammopathies
,” Klin. Onkol.
30
(Suppl 2
), 2S29
–2S34
(2017
). 4.
W. I.
Gonsalves
et al, “Quantification of clonal circulating plasma cells in relapsed multiple myeloma
,” Br. J. Haematol.
167
(4
), 500
–505
(2014
). 5.
W. I.
Gonsalves
et al, “Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
,” Leukemia
31
(1
), 130
–135
(2017
). 6.
S.
Mailankody
et al, “Minimal residual disease in multiple myeloma: Bringing the bench to the bedside
,” Nat. Rev. Clin. Oncol.
12
(5
), 286
–295
(2015
). 7.
N.
Berger
, S.
Kim-Schulze
, and S.
Parekh
, “Minimal residual disease in multiple myeloma: Impact on response assessment, prognosis and tumor heterogeneity
,” Adv. Exp. Med. Biol.
1100
, 141
–159
(2018
). 8.
B.
Paiva
, J. J. M.
Van Dongen
, and A.
Orfao
, “New criteria for response assessment: Role of minimal residual disease in multiple myeloma
,” Blood
125
(20
), 3059
–3069
(2016
). 9.
M. A.
Qasaimeh
et al, “Isolation of circulating plasma cells in multiple myeloma using CD138 antibody-based capture in a microfluidic device
,” Sci. Rep.
7
, 45681
(2017
). 10.
B.
Foulk
et al, “Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders
,” Br. J. Haematol.
180
(1
), 71
–81
(2018
). 11.
H. W.
Hou
et al, “Isolation and retrieval of circulating tumor cells using centrifugal forces
,” Sci. Rep.
3
(1
), 1259
(2013
). 12.
M.
Hayashi
et al, “Size-based detection of sarcoma circulating tumor cells and cell clusters
,” Oncotarget
8
(45
), 78965
–78977
(2017
). 13.
H.
Huebner
et al, “Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients
,” BMC Cancer
18
(1
), 204
(2018
). 14.
K.
Gregory
and D.
Basmadjian
, “An analysis of the contact phase of blood coagulation: Effects of shear rate and surface are intertwined
,” Ann. Biomed. Eng.
22
(2
), 184
–193
(1994
). 15.
Y.
Cinar
, A. M.
Senyol
, and K.
Duman
, “Blood viscosity and blood pressure: role of temperature and hyperglycemia
,” Am. J. Hypertens.
14
, 433
(2001
). 16.
Y.
Wan
, J.
Tan
, W.
Asghar
, Y. T.
Kim
, Y.
Liu
, and S. M.
Iqbal
, “Velocity effect on aptamer-based circulating tumor cell isolation in microfluidic devices
,” J. Phys. Chem. B
115
(47
), 13891
–13896
(2011
). 17.
H.
Chen
and X.
Sun
, “Laboratory characteristics of multiple myeloma and analysis of misdiagnosis
,” Chin. J. Clin. Pathol.
4
(4
), 1
(2012
). 18.
M. L.
Turgeon
, Clinical Hematology: Theory and Procedures
(Lippincott Williams & Wilkins
, 2004
).19.
H.
Daniels
, V. G.
Wheater
, and P. R.
Burkitt
, Functional Histology: A Text and Colour Atlas
(Churchill Livingstone
, Edinburgh
, 1979
).20.
Y.
Feng
et al.
, “Unique biomechanical interactions between myeloma cells and bone marrow stroma cells
,” Prog. Biophys. Mol. Biol.
103
, 148
(2010
). 21.
C.
Dong
and R.
Skalak
, “Leukocyte deformability: Finite element modeling of large viscoelastic deformation
,” J. Theor. Biol.
158
(2
), 173
–193
(1992
). 22.
H.
Zeng
and Y.
Zhao
, “Rheological analysis of non-Newtonian blood flow using a microfluidic device
,” Sens. Actuators A
166
, 207
–213
(2010
). 23.
J. L.
Li
, Y. R.
Liu
, Y.
Chang
, J. Y.
Fu
, and S. S.
Chen
, “[Immunophenotypic characteristics of multiple myeloma cells]
,” Zhongguo Shi Yan Xue Ye Xue Za Zhi
10
(3
), 226
–228
(2002
). 24.
S. J.
Tan
, L.
Yobas
, G. Y. H.
Lee
, C. N.
Ong
, and C. T.
Lim
, “Microdevice for the isolation and enumeration of cancer cells from blood
,” Biomed. Microdevices
11
(4
), 883
–892
(2009
). 25.
W.
Xu
, R.
Mezencev
, B.
Kim
, L.
Wang
, and J.
Mcdonald
, “Cell stiffness is a biomarker of the metastatic potential of ovarian cancer cells
,” PLoS One
7
(10
), 46609
(2012
). 26.
N. Y. L.
Lam
, T. H.
Rainer
, R. W. K.
Chiu
, Y. M. D.
Lo
, C. W. K.
Lam
, and Y. M. D.
Lo
, “EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis
,” Clin. Chem.
50
(1
), 256
–257
(2004
). 27.
K.
Boxshall
, M.-H.
Wu
, Z.
Cui
, Z.
Cui
, J. F.
Watts
, and M. A.
Baker
, “Simple surface treatments to modify protein adsorption and cell attachment properties within a poly(dimethylsiloxane) micro-bioreactor
,” Surf. Interface Anal.
38
(4
), 198
–201
(2006
). 28.
J. G.
Hollowell
, O. W.
van Assendelft
, E. W.
Gunter
, B. G.
Lewis
, M.
Najjar
, and C.
Pfeiffer
, “Hematological and iron-related analytes–reference data for persons aged 1 year and over: United States, 1988-94
,” Vital Health Stat.
11
(247
), 1
–156
(2005
).29.
G. N.
Lê
et al, “Current and future biomarkers for risk-stratification and treatment personalisation in multiple myeloma
,” Mol. Omics
15
(1
), 7
–20
(2019
). 30.
S. W.
Cotten
, Z.
Shajani-Yi
, M. A.
Cervinski
, T.
Voorhees
, S. A.
Tuchman
, and N.
Korpi-Steiner
, “Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: Implications for classification of patient results in a multi-center study
,” Clin. Biochem.
58
, 100
–107
(2018
). 31.
A. F.
Sarioglu
et al, “A microfluidic device for label-free, physical capture of circulating tumor cell clusters
,” Nat. Methods
12
(7
), 685
–691
(2015
). 32.
G.
Wang
, K.
Crawford
, C.
Turbyfield
, W.
Lam
, A.
Alexeev
, and T.
Sulchek
, “Microfluidic cellular enrichment and separation through differences in viscoelastic deformation
,” Lab Chip
15
(2
), 532
–540
(2015
). 33.
D. R.
Gossett
et al, “Label-free cell separation and sorting in microfluidic systems
,” Anal. Bioanal. Chem.
397
(8
), 3249
(2010
). © 2019 Author(s).
2019
Author(s)
You do not currently have access to this content.